Carla Eksteen

Dr. Carla Eksteen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Cancer Control
Verified
Journal Article
Open access
CECarla Eksteen
Carla Eksteen
JRJohann Riedemann
Johann Riedemann
ARAtarah M Rass
Atarah M Rass
MPManisha du Plessis
Manisha du Plessis
MBMatthys H Botha
Matthys H Botha
AEAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Cervical cancer is the fourth most common cancer in women. Advanced stage and metastatic disease are often associated with poor clinical outcomes. This substantiates the absolute necessity for high-throughput diagnostic and treatment platforms that are patient and tumour specific. Cervical cancer treatment constitutes multimodal intervention. Systemic treatments such as chemotherapy and/or focal radiotherapy are typically applied as neoadjuvant and/or adjuvant strategies. Cisplatin constitutes an integral part of standard cervical cancer treatment approaches. However, despite initial patient response, de novo or delayed/acquired treatment resistance is often reported, and toxicity is of concern. Chemotherapy resistance is associated with major alterations in genomic, metabolomic, epigenetic and proteomic landscapes. This results in imbalanced homeostasis associated with pro-oncogenic and proliferative survival, anti-apoptotic benefits, and enhanced DNA damage repair processes. Although significant developments in cancer diagnoses and treatment have been made over the last two decades, drug resistance remains a major obstacle to overcome.

15 November 2024 in Advances in Medical Sciences
Verified
Journal Article
Closed access
MMMadré Meyer
Madré Meyer
CECarla Eksteen
Carla Eksteen
HMHaynes Van Der Merwe
Haynes Van Der Merwe
MBMatthys H. Botha
Matthys H. Botha
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht

23 August 2024 in Biology
Verified
Journal Article
Open access
PDF file
DODaniel Wilhelm Olivier
Daniel Wilhelm Olivier
CECarla Eksteen
Carla Eksteen
MPManisha du Plessis
Manisha du Plessis
LJLouis De Jager
Louis De Jager
LELize Engelbrecht
Lize Engelbrecht
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Background: Previous research has shown that the Serum Amyloid A (SAA) protein family is intricately involved in inflammatory signaling and various disease pathologies. We have previously demonstrated that SAA is associated with increased colitis disease severity and the promotion of tumorigenesis. However, the specific role of SAA proteins in breast cancer pathology remains unclear. Therefore, we investigated the role of systemic SAA1 and SAA2 (SAA1/2) in a triple-negative breast cancer mouse model. Methods: Syngeneic breast tumors were established in wild-type mice, and mice lacking the SAA1/2 (SAADKO). Subsequently, tumor volume was monitored, species survival determined, the inflammatory profiles of mice assessed with a multiplex assay, and tumor molecular biology and histology characterized with Western blotting and H&E histological staining. Results: WT tumor-bearing mice had increased levels of plasma SAA compared to wild-type control mice, while SAADKO control and tumor-bearing mice presented with lower levels of SAA in their plasma. SAADKO tumor-bearing mice also displayed significantly lower concentrations of systemic inflammatory markers. Tumors from SAADKO mice overall had lower levels of SAA compared to tumors from wild-type mice, decreased apoptosis and inflammasome signaling, and little to no tumor necrosis. Conclusions: We demonstrated that systemic SAA1/2 stimulates the activation of the NLRP3 inflammasome in breast tumors, leading to the production of pro-inflammatory cytokines. This, in turn, promoted apoptosis and tumor necrosis but did not significantly impact tumor growth or histological grading.

11 June 2025 in Seminars in Oncology
Verified
Journal Article
Open access
CECarla Eksteen
Carla Eksteen
JRJohann Riedemann
Johann Riedemann
FMFrederick H. van der Merwe
Frederick H. van der Merwe
MBMatthys H. Botha
Matthys H. Botha
AEAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
The World Health Organization reports that cervical cancer ranks as the eighth most common cancer worldwide and is the ninth leading cause of cancer-related deaths. It is also the most prevalent cancer among women in 25 countries, primarily in Sub-Saharan Africa. Consequently, cervical cancer continues to pose a significant global health challenge, particularly due to the limited treatment options available for advanced stages of the disease. Evidently, immunotherapy is a promising strategy, but its efficacy is variable among patients. As such, predictive indicators are essential for identifying patients who are most likely to benefit from immunotherapy and for guiding treatment decisions. This review provides an overview of the current landscape of predictive biomarkers in cervical cancer immunotherapy, including immune checkpoint molecules, tumor mutational burden and immune cell infiltration. We further discuss additional factors such as cytokines, tumor infiltrating lymphocytes and previous exposure to platinum-based chemotherapy. As the field continues to evolve, ongoing research efforts are needed to refine predictive biomarkers and optimize patient selection in LMICs for immunotherapy in cervical cancer.

28 August 2022 in Experimental Cell Research
Verified
Journal Article
Closed access
CECarla Eksteen
Carla Eksteen
MPManisha du Plessis
Manisha du Plessis
JMJustin Mills
Justin Mills
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht

1 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
CSCayleigh de Sousa
Cayleigh de Sousa
CECarla Eksteen
Carla Eksteen
Anna-Mart EngelbrechtAnna-Mart Engelbrecht
Anna-Mart Engelbrecht
Background: Cervical cancer remains a leading cause of cancer‐related mortality among women globally. Persistent infection with high‐risk human papillomavirus drives cervical carcinogenesis, and treatment outcomes are frequently challenged by metastasis and chemoresistance. The transmembrane glycoprotein cluster of differentiation 44 (CD44), a marker associated with cancer stem cells (CSCs), has emerged as a critical mediator of both processes in cervical cancer. Objective: This review aims to critically evaluate current evidence on the role of CD44 in cervical cancer progression, metastasis, and treatment resistance. It also explores the potential of resveratrol, a naturally occurring polyphenol with known anticancer properties, as a chemo‐sensitizing agent to carboplatin therapy. Methods: A comprehensive review of the literature was conducted using databases such as PubMed, Google Scholar, and Scopus to identify studies that investigate CD44‐mediated mechanisms in cervical cancer, as well as the modulatory and mechanistic effects of resveratrol on CD44 and chemoresistance across various cancer types. Results: CD44 has been consistently implicated in promoting drug resistance, epithelial‐to‐mesenchymal transition (EMT), and stemness in cervical cancer. Resveratrol has demonstrated antimetastatic and chemo‐sensitizing effects in several malignancies, such as colorectal and breast cancers, often through modulation of CD44 and associated pathways. However, direct evidence in cervical cancer remains limited. Conclusion: Current findings suggest a promising therapeutic avenue for combining resveratrol with carboplatin to overcome CD44‐mediated treatment resistance and metastasis in cervical cancer. Nonetheless, further cervical‐specific studies are needed to validate this approach. A clearer understanding of this relationship may facilitate lower chemotherapy dosing, reduced toxicity, and improved clinical outcomes.